Doug Kass shares his views every day on RealMoneyPro. Click here for a real-time look at his insights and musings.
Reviewing the Large-Cap Fave Troops
Originally published March 28 at 10:54 a.m. EST
continues to plot a nice course despite today's general weakness in biotech.
This year AGN shares have experienced higher lows and higher highs -- a good thing. Hopefully a break above $250 a share could help to move the stock closer toward my year-end objectives this summer/early fall.
The company's fundamentals remain strong based on a recent review I undertook.
Speaking of faves...
Last year's favorite large-cap long, DuPont (DD) - Get Report , is now trading above $81 a share (I placed DD on my Best Ideas List in late January 2016 at $52.87). I am now down to tag ends on the name as the reward versus risk is no longer attractive.
Position: Long AGN large, DD small; short CAT small .
Oclaro (OCLR) - Get Report , the object of discussion in my Diary recently, continues to trade up with all its collaterals/competitors after the recent conference, which indicated that business fundamentals are on solid footing.
Clarity on Oclaro
Originally published March 28 at 1:50 p.m. EST
Other broad-based opticals-related tech companies like Lumentum (LITE) - Get Report and/or Acacia Communications (ACIA) - Get Report seem to be more likely takeover candidates in the next 12 months than OCLR.
Position: None .
Action Alerts PLUS, which Cramer manages as a charitable trust, is long AGN.